SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19 (BCYP)
Go back to SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19 (BCYP)| Blue Calypso, Inc. Common (NASDAQ: BCYP) | Delayed: 8.44 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.44 | 52 Week High | $3.80 | |||
| Open | $0.00 | 52 Week Low | $0.50 | |||
| Day High | $8.44 | P/E | N/A | |||
| Day Low | $8.44 | EPS | $-0.08 | |||
| Volume | 9,125,409 | |||||
| (NASDAQ: BCYPU) | Delayed: 8.57 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.57 | 52 Week High | $ | |||
| Open | $10.50 | 52 Week Low | $ | |||
| Day High | $8.57 | P/E | N/A | |||
| Day Low | $8.57 | EPS | $ | |||
| Volume | 1,382 | |||||
